Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Aug. 31, 2018
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 0	$ 30,000,000
Cash received in asset acquisition		0	15,500,000
Investments in affiliates		17,487,000		$ 18,859,000
Deferred revenue		79,124,000		$ 69,764,000
Write-off of in-process research and development acquired in asset acquisition		$ 0	8,721,000
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.
Business Acquisition [Line Items]
Investments in affiliates					$ 4,303,000
Ownership interest		100.00%
Deferred revenue	$ 10,078,000		$ 10,078,000
Write-off of in-process research and development acquired in asset acquisition	8,721,000
Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Cash received in asset acquisition	15,500,000
ActoBio Therapeutics Inc. | Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition	$ 30,000,000